Press Release

(February 11, 2020) - SAN DIEGO – TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced today the addition of two key executives to its leadership team.

Ray Kaczmarek joins TriLink as senior vice president of GMP operations. Kaczmarek, who has over 20 years of experience in pharmaceutical and biote...

(January 7, 2020) -

Advancements Expected to Accelerate Development of mRNA Therapeutics

SAN DIEGO (January 7, 2020) – TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids such as DNA and RNA, announced today that the United States Patent and Trademark Office has issued two new patents to the company. Both patents cover advanc...

(November 20, 2019) - mRNA Day is being celebrated in the City of San Diego following a proclamation in honor of Maravai LifeSciences and the grand opening of its new headquarters in the City. A leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide; Maravai invested $40 million into the 105,000 square-foot headquarters located in Sorrento Valley, which features a 50,000 square foot manufa...

(October 14, 2019) - Two New Sets of Barcode Convert Primers are Optimized for Ion Torrent* Sequencers

SAN DIEGO (October 14, 2019) – TriLink BioTechnologies, a Maravai LifeSciences company and leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, introduces two new primer sets for its CleanTag® kit. The new Ion Torrent Convert barcode primer sets e...

(November 29, 2018) - TriLink BioTechnologies, a Maravai LifeSciences company and a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, announced today that the company’s CleanTag® Small RNA Library Prep Kit was the enabling technology in a new study of next-generation sequencing of small RNAs from single cells. The study, Efficient Production of On-Target Reads for Small RNA Sequenci...

(October 9, 2018) - Maravai LifeSciences, a leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced that it has hired Christopher Shaffer as senior director of oligonucleotide process development for TriLink BioTechnologies. In this new position, Shaffer will develop and refine processes that improve overall efficiency and will be instrumental when TriLink relocates to a ...

(September 10, 2018) - Maravai LifeSciences, a leader in providing reagents to researchers, biotherapeutics manufacturers and OEM partners worldwide, today announced plans to relocate and expand its TriLink BioTechnologies operations with the signing of a lease on a new facility in the Sorrento Valley area of San Diego. TriLink will consolidate its San Diego facilities into a new 95,000-square-foot space with an option to expand for fut...

In the News

mRNA Day: TriLink, Maravai Look to RNA, Oligonucleotides, and San Diego for Growth

(Genetic Engineering & Biotechnology News: December 20, 2019) - A San Diego manufacturer of highly-modified nucleic acids and its parent company have concluded that development of RNA- and oligonucleotide-based therapeutics—as well as the region’s biopharma cluster—will both grow strongly enough in the near future to justify the companies’ recent $50-million investment in relocation and expansion within the city...

RNA Epitranscriptome: Role of the 5’ Cap

(Genetic Engineering & Biotechnology News: May 1, 2019) - Epigenetic modification of RNA, the RNA analog of the DNA epigenome, has been observed for over 40 years and is known as the epitranscriptome. Messenger RNAs (mRNAs) in particular are post-transcriptionally modified, obtaining base modifications as well as 2ʹ methylation of sugars near the 5ʹ cap. Cap modifications identify the mRNA as self rather than foreign, and modulate stability, translation, decappin...

Address Manufacturing and Look Beyond Cancer, Panel Advises Cell and Gene Therapy Companies

(Genetic Engineering & Biotechnology News: March 22, 2019) - The ability of cell and gene therapy companies to raise capital this year will hinge on their ability to address the manufacturing of their products as well as address medical needs beyond cancer, a panel of three investors and an industry executive agreed yesterday...

Jennifer Dahlgren
Dahlgren Communications
Phone: (530) 263-6817
Email: [email protected]


David Weber, Chief Commercial Officer
Maravai LifeSciences
Phone: (650) 697-3600
Email: [email protected]